Clinical usefulness of post-treatment FDG PET/CT in patients with ovarian malignancy

Han, Eun Ji; Park, Hye Lim; Lee, Yong Seok; Park, Eun Kyung; Song, Min Jong; Yoo, Ie Ryung; Kim, Sung Hoon; Choi, Woo Hee

doi:10.1007/s12149-016-1100-0

Cited by 15 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further to clinical examination and checking for symptoms, CA-125 is the simplest tool to trigger imaging and is a better approach than regular routine imaging for diagnosis of recurrent ovarian cancer [244,251]. Radiographic imaging, such as ultrasound, chest-abdomen-pelvis CT, whole-body MRI or PET-CT, should only be carried out if clinically indicated, based on symptoms, clinical examination or a rising CA-125 level [252][253][254][255]. Mucinous and clear cell ovarian cancers could represent a potential source of PET-negative findings [256].…”

Section: Recurrent Diseasementioning

confidence: 99%

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Banerjee²,

et al. 2019

View full text Add to dashboard Cite

These consensus statements were developed by the European Society for Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO) and are published jointly in the Annals of Oncology and the International Journal of Gynecological Cancer. The two societies nominated participants who attended the consensus conference and co-authored the final manuscript. ‡ See Appendix for members of the ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. The development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO-ESGO consensus conference on ovarian cancer was held on 12-14 April 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. The recommendations presented here are thus based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO-ESGO consensus conference, together with a summary of evidence supporting each recommendation.

show abstract

Section: Recurrent Diseasementioning

confidence: 99%

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Banerjee²,

et al. 2019

View full text Add to dashboard Cite

show abstract

“…244 251 Radiographic imaging, such as ultrasound, chest-abdomen-pelvis CT, whole-body MRI or PET-CT, should only be carried out if clinically indicated, based on symptoms, clinical examination or a rising CA125 level. [252][253][254][255] Mucinous and clear cell…”

Section: Original Articlementioning

confidence: 99%

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Colombo

Sessa

Bois

et al. 2019

Int J Gynecol Cancer

351

468

View full text Add to dashboard Cite

The development of guidelines is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO–ESGO consensus conference on ovarian cancer was held on April 12–14, 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. The recommendations presented here are thus based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO–ESGO consensus conference, together with a summary of evidence supporting each recommendation.

show abstract

“…Despite the fact that the role of imaging techniques or serum tumor markers in asymptomatic patients remains controversial, their use in symptomatic patients is advocated . The diagnostic performance of these diagnostic tools varies among the different techniques, but, in general, all of them have acceptable results . However, none of them is 100% specific.…”

mentioning

confidence: 99%

“…[1][2][3][4] The diagnostic performance of these diagnostic tools varies among the different techniques, but, in general, all of them have acceptable results. [5][6][7] However, none of them is 100% specific.…”

mentioning

confidence: 99%

Gastrointestinal Endoscopic Ultrasound‐Guided Fine‐Needle Aspiration for Assessing Suspected Deep Pelvic or Abdominal Recurrence in Gynecologic Cancer: A Feasibility Study

Súbtil

Alcázar

Betés

et al. 2018

J of Ultrasound Medicine

View full text Add to dashboard Cite

show abstract

Clinical usefulness of post-treatment FDG PET/CT in patients with ovarian malignancy

Abstract: Post-treatment PET/CT was a useful modality for the detection of disease recurrence or second primary malignancy that could improve the likelihood of proper treatment and help predict outcome in patients with ovarian malignancy.

Cited by 15 publications

References 27 publications

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Gastrointestinal Endoscopic Ultrasound‐Guided Fine‐Needle Aspiration for Assessing Suspected Deep Pelvic or Abdominal Recurrence in Gynecologic Cancer: A Feasibility Study

Contact Info

Product

Resources

About